Trending NewsTrending NewsNYSE:HIMS Hims & Hers Health (HIMS) Stock Price, News & Analysis $27.44 +0.00 (+0.01%) Closing price 09/11/2026 03:58 PM EasternExtended Trading$27.48 +0.04 (+0.13%) As of 09/11/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Hims & Hers Health Stock (NYSE:HIMS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hims & Hers Health alerts:Sign Up Key Stats Today's Range$26.73▼$27.6350-Day Range$24.97▼$38.3452-Week Range$13.74▼$65.30Volume7.07 million shsAverage Volume10.39 million shsMarket Capitalization$6.40 billionP/E RatioN/ADividend YieldN/APrice Target$32.43Consensus RatingHold Company Overview Hims & Hers Health, Inc. is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate. Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners. The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings. Hims & Hers serves customers primarily in the United States, with operations also available in select international markets. Andrew Dudum is the company’s co-founder and chief executive officer.AI Generated. May Contain Errors. Read More Hims & Hers Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreHIMS MarketRank™: Hims & Hers Health scored higher than 54% of companies evaluated by MarketBeat, and ranked 483rd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingHims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 3 buy ratings, 12 hold ratings, and 1 sell rating.Upside PotentialHims & Hers Health has a consensus price target of $32.43, representing about 18.2% upside from its current price of $27.44.Amount of Analyst CoverageHims & Hers Health has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Hims & Hers Health's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Hims & Hers Health are expected to grow in the coming year, from ($0.10) to $0.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is -43.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is -43.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 11.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Hims & Hers Health's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted26.69% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 4.33.Change versus previous monthShort interest in Hims & Hers Health has recently decreased by 6.36%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.17 News SentimentHims & Hers Health has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 35 news articles for Hims & Hers Health this week, compared to 9 articles on an average week.Search InterestOnly 28 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.MarketBeat FollowsOnly 17 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,133,613.00 in company stock.Percentage Held by Insiders11.76% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hims & Hers Health's insider trading history. Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HIMS Stock News HeadlinesINVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - HIMS1 hour ago | globenewswire.comROSEN, NATIONAL TRIAL COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSSeptember 13 at 12:00 PM | globenewswire.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.September 13 at 1:00 AM | Banyan Hill Publishing (Ad)I'm Calling It: Hims & Hers Health Will Soar 56% by the End of 2026September 13 at 4:15 AM | fool.comHims & Hers Health (NYSE:HIMS) Insider Sells $97,965.14 in StockSeptember 4, 2026 | insidertrades.comMarketBeat Week in Review – 08/24 - 08/28 (HIMS)MarketBeat analysts recap a mixed earnings week, covering AI infrastructure demand, retail's K-shaped consumer trends, Meta's $18 billion settlement, and stock picks across tech, biotech, and retail sectors.August 29, 2026 | marketbeat.comVisa Just Put Hims & Hers in the Penalty Box—Here’s Why It MattersVisa placed Hims & Hers Health into its Acquirer Monitoring Program after a billing dispute spike, adding penalty costs amid an FTC lawsuit and margin contraction.August 24, 2026 | marketbeat.comHims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 4,938 SharesAugust 21, 2026 | insidertrades.comSee More Headlines HIMS Stock Analysis - Frequently Asked Questions How have HIMS shares performed this year? Hims & Hers Health's stock was trading at $32.45 at the start of the year. Since then, HIMS shares have decreased by 15.4% and is now trading at $27.4430. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) posted its quarterly earnings data on Monday, August, 10th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.32. Hims & Hers Health's revenue for the quarter was up 38.2% compared to the same quarter last year. Read the conference call transcript. Is Hims & Hers Health doing a stock buyback? Hims & Hers Health's board initiated a stock buyback program on Monday, November 17th 2025, which permits the company to repurchase $250,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 3% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's leadership believes its shares are undervalued. Who are Hims & Hers Health's major shareholders? Top institutional shareholders of Hims & Hers Health include California State Teachers Retirement System (3.43%), Bank of New York Mellon Corp (0.58%), Bienville Capital Management LLC (0.34%) and FirstWave Capital Management LLC (0.15%). Insiders that own company stock include Melissa Baird, Michael Chi, Soleil Boughton, Oluyemi Okupe, David B Wells, Patrick Harrison Carroll, Christopher D Payne, Andrew Dudum, Garcia Andrea G Perez, Deborah M Autor, Christiane Pendarvis, Irene Becklund, Irene Becklund, Anja Manuel and Lynne Chou O'keefe. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hims & Hers Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/10/2026Today9/13/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 HIMS's financial health is in the Green zone, according to TradeSmith. HIMS has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNYSE:HIMS CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees2,442Year Founded2017Price Target and Rating Average Price Target for Hims & Hers Health$32.43 High Price Target$60.00 Low Price Target$23.00 Potential Upside/Downside+18.2%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$128.37 million Net Margins-5.51% Pretax Margin-6.35% Return on Equity-6.51% Return on Assets-1.20% Debt Debt-to-Equity Ratio4.21 Current Ratio0.93 Quick Ratio0.87 Sales & Book Value Annual Sales$2.35 billion Price / Sales2.73 Cash Flow$0.83 per share Price / Cash Flow32.87 Book Value$2.38 per share Price / Book11.53Miscellaneous Outstanding Shares233,310,000Free Float205,875,000Market Cap$6.40 billion OptionableOptionable Beta2.42 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NYSE:HIMS) was last updated on 9/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hims & Hers Health With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.